GT200900210A - Compuestos triciclicos y su uso como moduladores del receptor de glucocorticoides - Google Patents

Compuestos triciclicos y su uso como moduladores del receptor de glucocorticoides

Info

Publication number
GT200900210A
GT200900210A GT200900210A GT200900210A GT200900210A GT 200900210 A GT200900210 A GT 200900210A GT 200900210 A GT200900210 A GT 200900210A GT 200900210 A GT200900210 A GT 200900210A GT 200900210 A GT200900210 A GT 200900210A
Authority
GT
Guatemala
Prior art keywords
glucocorticoid receptor
modulators
compounds
triciclic
triciclic compounds
Prior art date
Application number
GT200900210A
Other languages
English (en)
Inventor
Hu Xiao
Jerome Kevin Dewayne
Obukowicz Mark Gerard
Webber Ronald Keith
Olson Lisa
Rucker Paul Vincent
Crescenzo Gary A De
Devraj Rajesh Venkateswaran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900210A publication Critical patent/GT200900210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS QUE SON MODULADORES DE RECEPTOR DE GLUCOCORTICOIDES QUE SON DE UTILIDAD PARA TRATAR UNA VARIEDAD DE AFECCIONES DEBIDO A SU POTENTE ACTIVIDAD ANTIINFLAMATORIA, ANTIPROLIFERATIVA E INMUNOMODULADORA.
GT200900210A 2007-02-02 2009-07-30 Compuestos triciclicos y su uso como moduladores del receptor de glucocorticoides GT200900210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
GT200900210A true GT200900210A (es) 2010-04-05

Family

ID=39315208

Family Applications (2)

Application Number Title Priority Date Filing Date
GT200900209A GT200900209A (es) 2007-02-02 2009-07-30 Compuestos triciclos y su uso como moduladores del receptor de glucocorticosteroides
GT200900210A GT200900210A (es) 2007-02-02 2009-07-30 Compuestos triciclicos y su uso como moduladores del receptor de glucocorticoides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GT200900209A GT200900209A (es) 2007-02-02 2009-07-30 Compuestos triciclos y su uso como moduladores del receptor de glucocorticosteroides

Country Status (43)

Country Link
US (7) US7547714B2 (es)
EP (1) EP2114970B1 (es)
JP (1) JP4599462B2 (es)
KR (2) KR101107949B1 (es)
CN (2) CN101616925B (es)
AP (1) AP2455A (es)
AR (2) AR065134A1 (es)
AT (1) ATE518872T1 (es)
AU (1) AU2008211613B2 (es)
BR (1) BRPI0808634A2 (es)
CA (1) CA2676670C (es)
CL (2) CL2008000330A1 (es)
CO (2) CO6220937A2 (es)
CR (2) CR10949A (es)
CU (2) CU20090133A7 (es)
CY (2) CY1110962T1 (es)
DK (1) DK2114970T3 (es)
DO (1) DOP2009000190A (es)
EA (1) EA016494B1 (es)
EC (2) ECSP099552A (es)
ES (2) ES2368286T3 (es)
GE (2) GEP20125404B (es)
GT (2) GT200900209A (es)
HK (1) HK1135108A1 (es)
HN (2) HN2008000179A (es)
HR (1) HRP20110702T1 (es)
IL (1) IL199972A (es)
MA (2) MA31117B1 (es)
MX (1) MX2009008284A (es)
MY (3) MY146087A (es)
NI (2) NI200900149A (es)
NZ (1) NZ578638A (es)
PE (2) PE20081736A1 (es)
PL (1) PL2114970T3 (es)
PT (2) PT2114970E (es)
RS (2) RS51970B (es)
SI (1) SI2114970T1 (es)
SV (2) SV2009003346A (es)
TN (1) TN2009000324A1 (es)
TW (2) TWI347842B (es)
UA (2) UA94639C2 (es)
WO (1) WO2008093227A1 (es)
ZA (2) ZA200906064B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
WO2008093227A1 (en) * 2007-02-02 2008-08-07 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
MX2011001053A (es) * 2008-07-28 2011-04-21 Pfizer Compuestos de fenantrenona, composiciones y metodos.
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137843A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Delivery devices for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
EP2569307A2 (en) 2010-05-10 2013-03-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
WO2012027702A1 (en) * 2010-08-27 2012-03-01 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators
AU2012229952A1 (en) * 2011-03-15 2013-04-18 Abbvie Inc. Nuclear hormone receptor modulators
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) * 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
DK3142637T3 (da) 2014-05-16 2020-08-24 Olaplex Inc Keratin treatment formulations and methods
BR112017008097B1 (pt) * 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
CN113350353A (zh) 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
CN114432313A (zh) 2016-04-07 2022-05-06 奥伊斯特普安生物制药公司 治疗眼部病状的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
PL207610B1 (pl) 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
WO2001005229A1 (en) 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
IL180679A0 (en) * 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
ES2262612T3 (es) * 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
DE10196880T1 (de) * 2000-11-20 2003-12-18 Seagate Technology Llc RF-ID-Tag-Attachment an ein Plattenlaufwerk
US20030170309A1 (en) 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
MXPA04001893A (es) 2001-08-31 2005-03-07 Corcept Therapeutics Inc Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down.
CA2460144C (en) 2001-09-27 2010-11-02 Universite De Liege Pyridinic sulfonamide derivatives, method of production and use thereof
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
AU2003281355A1 (en) 2002-07-08 2004-01-23 Pfizer Products Inc. Modulators of the glucocorticoid receptor
JP2006507311A (ja) 2002-11-05 2006-03-02 コーセプト セラピューティクス， インコーポレイテッド 胃食道逆流性疾患を処置するための方法
WO2004069202A2 (en) 2003-02-04 2004-08-19 Corcept Therapeutics, Inc Antiglucocorticoids for the treatment of postpartum psychosis
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
JP4976852B2 (ja) * 2003-11-10 2012-07-18 ザ スクリプス リサーチ インスティチュート 細胞脱分化を誘導するための組成物および方法
AU2004289532A1 (en) * 2003-11-13 2005-05-26 Pfizer Products Inc. Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
JP2009535430A (ja) 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
WO2008093227A1 (en) * 2007-02-02 2008-08-07 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
JP4579333B2 (ja) * 2007-02-02 2010-11-10 ファイザー・プロダクツ・インク 三環式化合物およびそれらのグルココルチコイド受容体調節剤としての使用

Also Published As

Publication number Publication date
TW200838514A (en) 2008-10-01
CA2676670C (en) 2012-03-13
US20080188443A1 (en) 2008-08-07
SV2009003346A (es) 2010-04-13
CN101616896B (zh) 2012-07-04
PT2114888E (pt) 2011-01-04
NI200900148A (es) 2010-02-15
HN2008000178A (es) 2011-02-25
ES2353822T3 (es) 2011-03-07
ZA200906064B (en) 2010-05-26
AP2009004942A0 (en) 2009-08-31
SV2009003349A (es) 2010-04-13
IL199972A (en) 2013-09-30
CL2008000329A1 (es) 2008-08-08
CR10948A (es) 2009-08-07
DK2114970T3 (da) 2011-09-19
CO6190603A2 (es) 2010-08-19
US7786097B2 (en) 2010-08-31
ATE518872T1 (de) 2011-08-15
CL2008000330A1 (es) 2008-08-08
BRPI0808634A2 (pt) 2014-08-05
GEP20125404B (en) 2012-02-27
KR20090107080A (ko) 2009-10-12
TWI347842B (en) 2011-09-01
HRP20110702T1 (hr) 2011-10-31
AR065135A1 (es) 2009-05-20
DOP2009000190A (es) 2009-08-31
AU2008211613A1 (en) 2008-08-07
WO2008093227A1 (en) 2008-08-07
TW200846325A (en) 2008-12-01
RS51970B (en) 2012-02-29
CY1111758T1 (el) 2015-10-07
AU2008211613B2 (en) 2013-05-23
US20120088802A9 (en) 2012-04-12
CU23824A3 (es) 2011-10-31
KR101114682B1 (ko) 2012-03-14
US20120095062A1 (en) 2012-04-19
JP4599462B2 (ja) 2010-12-15
US20100286214A1 (en) 2010-11-11
US20140142316A1 (en) 2014-05-22
MY146087A (en) 2012-06-29
AP2455A (en) 2012-08-31
CO6220937A2 (es) 2010-11-19
CA2676670A1 (en) 2008-08-07
CN101616896A (zh) 2009-12-30
US8445520B2 (en) 2013-05-21
GT200900209A (es) 2010-07-22
HN2008000179A (es) 2010-06-09
JP2010517990A (ja) 2010-05-27
SI2114970T1 (sl) 2011-11-30
EA200970666A1 (ru) 2010-02-26
CU23848B1 (es) 2012-10-15
UA94639C2 (ru) 2011-05-25
MX2009008284A (es) 2009-08-12
GEP20125426B (en) 2012-03-26
KR20090108115A (ko) 2009-10-14
US20090281148A1 (en) 2009-11-12
HK1135108A1 (en) 2010-05-28
PT2114970E (pt) 2011-09-22
AR065134A1 (es) 2009-05-20
NI200900149A (es) 2010-02-15
CY1110962T1 (el) 2015-06-11
ZA200906060B (en) 2010-05-26
US20140316139A1 (en) 2014-10-23
PE20081736A1 (es) 2008-11-28
US8158660B2 (en) 2012-04-17
US20080312294A1 (en) 2008-12-18
CR10949A (es) 2009-08-07
ECSP099552A (es) 2009-08-28
PE20090113A1 (es) 2009-02-13
CN101616925B (zh) 2012-05-23
CU20090132A7 (es) 2011-10-14
UA95332C2 (uk) 2011-07-25
EP2114970A1 (en) 2009-11-11
MY148780A (en) 2013-05-31
PL2114970T3 (pl) 2011-11-30
MA31117B1 (fr) 2010-01-04
ES2368286T3 (es) 2011-11-16
TWI373466B (en) 2012-10-01
RS51646B (en) 2011-10-31
US7598231B2 (en) 2009-10-06
US7547714B2 (en) 2009-06-16
IL199972A0 (en) 2010-04-15
MY153057A (en) 2014-12-31
EP2114970B1 (en) 2011-08-03
CN101616925A (zh) 2009-12-30
MA31158B1 (fr) 2010-02-01
EA016494B1 (ru) 2012-05-30
CU20090133A7 (es) 2011-10-31
KR101107949B1 (ko) 2012-02-08
TN2009000324A1 (fr) 2010-12-31
US8901310B2 (en) 2014-12-02
NZ578638A (en) 2010-12-24
ECSP099553A (es) 2009-08-28

Similar Documents

Publication Publication Date Title
GT200900210A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticoides
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CO6501131A2 (es) Antagonistas de espiro-oxindol de mdm2
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
SV2010003593A (es) Nuevos herbicidas
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
EA200901597A1 (ru) Гербицидно активные бициклические 1,3-дионы
CR20140476A (es) Agentes para tratar transtornos que implican la modulación de receptores de rianodina
ECSP109923A (es) Bromhidrato de bupropion y aplicaciones terapéuticas
ECSP088648A (es) Nuevos bencimidazoles 2-sustituidos como moduladores de receptor de androgeno selectivos (sarms)
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
PA8623501A1 (es) Modulares de receptores de androgenos
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
PA8796001A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
UY34670A (es) Planta para la producción de peróxido de hidrógeno y proceso para su uso
DOP2006000290A (es) Moduladores de estrógenos